Mean pulmonary artery wall shear stress (WSS) may serve as a novel indicator of PA remodeling in PH patients. The study's small sample size and focus on PA flow limit its findings, necessitating ...

Pulmonary arterial hypertension (PAH) is a vascular remodeling disease that pathologically increases pulmonary vascular resistance. Ultimately, this leads to right ventricular failure and ...

SERT & Pulmonary Vascular Remodeling . There is much evidence to suggest that the SERT is involved in mediating the proliferative effects of serotonin in pulmonary arterial smooth muscle cells.

BMPER attenuated PI3K/AKT signaling and suppressed BMP4-driven smooth muscle activation in models of PAH. BMPER overexpression mitigated the vascular remodeling that characterizes pulmonary arterial ...

Targeting Fibroblast Activation Protein for Molecular Imaging of Fibrotic Remodeling in Pulmonary Arterial Hypertension. Journal of Nuclear Medicine , 2025; 66 (1): 98 DOI: 10.2967/jnumed.124. ...

BOSTON, MA—Denervation of the pulmonary artery (PA) in patients with Group 1 pulmonary arterial hypertension (PAH) led to a significant increase in 6-minute walk test distance as well as positive ...

“This medication is potentially reverse remodeling what has happened to the blood vessels in pulmonary arterial hypertension.” For the trial, researchers looked at people on the standard of ...

Pulmonary artery denervation has become a promising therapeutic intervention in the management of pulmonary hypertension. While our findings suggest a substantial role for PADN in treatment ...

NEW ORLEANS — Sotatercept, a novel activin signaling inhibitor, reduced risk for death and clinical worsening by 84% in patients with pulmonary arterial hypertension compared with placebo ...

Pulmonary arterial hypertension (PAH), characterized by vasoconstriction and pulmonary vascular remodeling, has a 10% annual mortality rate among patients due to right heart failure. There are genetic ...

Notably, patients in the sotatercept arm of the trial were much less likely to die or experience a clinical worsening event over a median 32.7 weeks (5.5% vs 26.3%, HR 0.16, 95% CI 0.08-0.35).

A new molecular imaging technique—18F-FAPI PET—can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing physicians with an early marker ...